What does micromicrobiotica do? Microbiotica has programs in IBD, immune-oncology and Clostridium difficile, developing medicines and biomarkers based on microbiota. These programs start with deep metagenomic and culture-based analysis of patient samples linked to phenotype before testing of candidate bacteria in advanced human in vitro and in vivo models.What is the microbiotica platform? The Microbiotica platform is based on world leading tools developed at the Wellcome Sanger Institutethat unblock the barriers to discovery. These are founded on a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling precise association of bacteria to function for the first time.Why choose microbiotix? As a testament to our innovation, Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies. The Company's lead therapeutic compound, MBX-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV).
Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co Mike Romanos's email & phone Microbiotica's Chief Executive Officer email